Enfusion Inc
Enfusion, Inc. provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief invest… Read more
Enfusion Inc (ENFN) - Total Liabilities
Latest total liabilities as of December 2024: $43.72 Million USD
Based on the latest financial reports, Enfusion Inc (ENFN) has total liabilities worth $43.72 Million USD as of December 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Enfusion Inc - Total Liabilities Trend (2019–2024)
This chart illustrates how Enfusion Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Enfusion Inc Competitors by Total Liabilities
The table below lists competitors of Enfusion Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Spearhead Integrated Marketing
SHE:300071
|
China | CN¥926.44 Million |
|
Indegene Ltd
NSE:INDGN
|
India | ₹7.10 Billion |
|
Johns LYNG Group Ltd
AU:JLG
|
Australia | AU$524.22 Million |
|
Jiangsu Baoli Asphalt
SHE:300135
|
China | CN¥687.40 Million |
|
SunOpta Inc.
NASDAQ:STKL
|
USA | $516.07 Million |
|
Canada Goose Holdings Inc
NYSE:GOOS
|
USA | $1.21 Billion |
|
Gravita India Limited
NSE:GRAVITA
|
India | ₹6.06 Billion |
|
Jiangsu Yangdian Science & Technology Co. Ltd.
SHE:301012
|
China | CN¥388.53 Million |
Liability Composition Analysis (2019–2024)
This chart breaks down Enfusion Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.42 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.60 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.31 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Enfusion Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Enfusion Inc (2019–2024)
The table below shows the annual total liabilities of Enfusion Inc from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $43.72 Million | +38.84% |
| 2023-12-31 | $31.49 Million | +54.83% |
| 2022-12-31 | $20.34 Million | +135.30% |
| 2021-12-31 | $8.64 Million | -96.83% |
| 2020-12-31 | $272.66 Million | +93.27% |
| 2019-12-31 | $141.08 Million | -- |